Why the study?
Do synthetic GP IIb/IIIa inhibitors reduce ischemic events in patients with coronary intervention, stents, unstable angina, and non-Q-wave infarction?
Population
Patients with high- and low-risk coronary intervention, stents, unstable angina, and non-Q-wave infarction
Design
Review
Follow-up
6 months
Authors
Loading...
May reduce periprocedural ischemic events without preventing restenosis; leaves open optimal agent selection and duration in contemporary PCI.
Do synthetic GP IIb/IIIa inhibitors reduce ischemic events in patients with coronary intervention, stents, unstable angina, and non-Q-wave infarction?
Synthetic GP IIb/IIIa inhibitors reduce ischemic events in acute coronary syndromes and PCI but do not prevent restenosis and may increase bleeding risk compared to abciximab.
Marc Verstraete (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: